The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 04, 2016

Filed:

Aug. 09, 2012
Applicants:

Takuya Tsunoda, Kanagawa, JP;

Ryuji Osawa, Kanagawa, JP;

Sachiko Yoshimura, Kanagawa, JP;

Tomohisa Watanabe, Kanagawa, JP;

Yusuke Nakamura, Tokyo, JP;

Inventors:

Takuya Tsunoda, Kanagawa, JP;

Ryuji Osawa, Kanagawa, JP;

Sachiko Yoshimura, Kanagawa, JP;

Tomohisa Watanabe, Kanagawa, JP;

Yusuke Nakamura, Tokyo, JP;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 7/00 (2006.01); A61K 38/10 (2006.01); C12N 9/00 (2006.01); A61K 39/00 (2006.01); C07K 14/47 (2006.01); C12N 9/14 (2006.01); G01N 33/50 (2006.01); C12N 5/0784 (2010.01); C12N 5/10 (2006.01); G01N 33/574 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C12N 9/93 (2013.01); A61K 39/00 (2013.01); A61K 39/0011 (2013.01); C07K 14/4738 (2013.01); C12N 5/0639 (2013.01); C12N 5/10 (2013.01); C12N 9/14 (2013.01); C12Y 306/04004 (2013.01); G01N 33/505 (2013.01); G01N 33/57407 (2013.01); A61K 38/00 (2013.01); C12N 2502/1114 (2013.01); G01N 2440/14 (2013.01);
Abstract

As discussed in greater detail herein, isolated epitope peptides derived from MPHOSPH1 bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above-mentioned MPHOSPH1-derived amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite CTL inducibility of the original sequences. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical agents or compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, and pharmaceutical agents or compositions of this invention find particular utility in either or both of the treatment and prevention of cancers and tumors, including, for example, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, gastric cancer, NSCLC, lymphoma, osteosarcoma, prostate cancer, renal cancer and soft tissue tumor.


Find Patent Forward Citations

Loading…